CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Cheetah® non-invasive cardiac monitoring system +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04474704
NCT04474704N/ACompleted
CompareCT.gov

Use of Cheetah® Non-invasive Cardiac Monitoring System to Guide Discontinuation of Postpartum Magnesium Sulfate in Women With Severe Preeclampsia: A Pilot Randomized Control Trial

Ohio State University·interventional·Posted Jul 17, 2020·Updated Jun 28, 2023

In Brief

A clinical study evaluating Cheetah® non-invasive cardiac monitoring system and Standard of care for Preeclampsia With Severe Features. Completed, enrolled 53 participants across 1 site.

Detailed Summary

This is a single site pilot randomized, controlled, trial randomizing patients with PE with severe features to one of 2 groups: * 24 hours of postpartum magnesium sulfate (current arbitrary standard of care) * Using the Cheetah® device to aid in an individualized duration of magnesium sulfate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia With Severe Features
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 17, 2020
Enrollment StartFeb 22, 2021
Primary CompletionApr 1, 2022
Study CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.0 years ago

Interventions

Cheetah® non-invasive cardiac monitoring systemdevice

Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))

Standard of careother

24 hours of postpartum magnesium sulfate